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Abstract Cell death is critical to normal homeostasis,
although this process, when increased aberrantly, can lead
to the production of pro-inﬂammatory mediators promot-
ing autoimmunity. Two novel intercellular mediators of
inﬂammation generated during cell death are high mobility
group box 1 (HMGB1) protein and microparticles (MPs).
HMGB1 is a nuclear protein that functions in transcription
when inside the nucleus but takes on pro-inﬂammatory
properties when released during cell death. Microparticles
are small, membrane-bound structures that extrude from
cells when they die and contain cell surface proteins and
nuclear material from their parent cells. MPs circulate
widely throughout the vasculature and mediate long-dis-
tancecommunicationbetweencells.BothMPsandHMGB1
havebeenimplicatedinthepathogenesisofabroadspectrum
of inﬂammatory diseases, including the prototypic auto-
immune conditions systemic lupus erythematosus and
rheumatoid arthritis. Given their range of activity and asso-
ciation with active disease, both structures may prove to be
targets for effective therapy in these and other disorders.
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Introduction
Cell death is a ubiquitous and inevitable process that
normally occurs without clinically evident immunologic
sequelae. In the setting of inﬂammatory and autoimmune
diseases, however, an increase in the extent of cell death or
defects in the clearance of dead cell debris may contribute
signiﬁcantly to immune disturbances underlying autoim-
munity. An increasing body of evidence suggests that two
major products of cell death, extracellular high mobility
group box protein 1 (HMGB1) and cellular microparticles
(MPs), have important roles in inﬂammation and the
pathogenesis of prototypic autoimmune conditions such as
rheumatoid arthritis (RA) and systemic lupus erythemato-
sus (SLE). These structures may also arise during cell
activation, although the close linkage between immune cell
activation and activation-induced cell death may compli-
cate interpretation of their origin.
Both HMGB1 and MPs are released during the death of
cells, and both induce pro-inﬂammatory cytokine expres-
sion, as illustrated in Fig. 1. HMGB1 is a non-histone,
DNA-binding nuclear protein that has dual function.
Within the nucleus, HMGB1 binds to DNA and regulates
transcription and chromosome architecture. In its extra-
cellular form, however, HMGB1 functions as a
pro-inﬂammatory cytokine. In contrast, MPs are small,
membrane-bound vesicles that display surface markers and
nucleic components characteristic of the parent cells.
While MPs are present in the peripheral blood of healthy
individuals, marked elevations occur in many disease states
characterized by high cell turnover or cell death. Further-
more, MPs can function as disease effectors, playing a role
in local and long-range signaling in cellular processes that
underlie inﬂammation and thrombosis. The association
between increased blood levels of HMGB1 and MPs with
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DOI 10.1007/s10165-008-0054-zactive disease provides tantalizing new clues about the
mechanisms of inﬂammation in autoimmunity, and sug-
gests potential targets for therapeutic intervention.
HMGB1 and its function
HMGB1isa30 kDanon-histone,chromatin-bindingprotein
ubiquitously expressed in eukaryotic cells and highly pre-
served across mammalian species [1]. HMGB1 contains 215
amino acids and has a tripartite structure consisting of two
DNA-binding domains, the A box and the B box, and a
C-terminaltaildomain[2,3].Unlikehistones,HMGB1binds
to DNA with low afﬁnity and can move from the nucleus to
the cytoplasm depending upon cell cycle phase [4].
Functionally, the role of HMGB1 depends upon its
location. When inside the nucleus, HMGB1 acts as an
architectural protein that binds to DNA and can impact
transcription. HMBG1 recognizes particular DNA confor-
mations (e.g., bent DNA) rather than speciﬁc nucleic acid
sequences and binds in the minor groove of the DNA helix.
As a result, HMGB1 can distort DNA and thereby enhance
interactions with several proteins, including p53, NF-jB,
progesterone receptors, estrogen receptors, and gluco-
corticoid receptors [5–7]. HMGB1 appears essential for
survival, as suggested by its evolutionary conservation as
well as the observation that HMGB1 knockout mice suc-
cumb to hypoglycemia within 24 h of birth; death in the
knockout mice likely results from impaired activation of
glucocorticoid receptor-responsive genes [8]. Thus, by
recognizing DNA and modifying its structure, HMGB1
plays an important role in transcriptional regulation. In
addition to its nuclear form, a cell-membrane form of
HMGB1 (also known as amphoterin or p30) promotes
neurite outgrowth, smooth muscle cell chemotaxis, and
tumor cell metastasis [9–11].
Once outside the cell, HMGB1 has an entirely different
role and functions as a pro-inﬂammatory cytokine with
effects similar to TNFa. In vitro studies using puriﬁed
HMGB1 demonstrate immunological activities likely
implicated in inﬂammatory disease. Although the activity
of HMGB1 preparations varies depending on the condi-
tions of isolation and puriﬁcation, both native and
recombinant forms of this protein can induce expression of
pro-inﬂammatory cytokines in vitro, including TNF-a, IL-
1, IL-6 and nitric oxide (NO) in neutrophils, macrophages
and pituicytes [12–14]. As a mediator of endothelial
function, HMGB1 activates human umbilical venular
endothelial cells (HUVEC) to upregulate adhesion mole-
cules, and activated HUVEC cells release HMGB1 [15,
16]. Among its other functions, HMGB1 can also promote
dendritic cell maturation and migration in vitro [17, 18].
The signaling systems triggered by HMGB1 are not
fully understood, although receptor for advanced glycation
end products (RAGE) is one receptor for HMBG-1. RAGE
belongs to the IgG superfamily and is present on the sur-
face of many cell types [19]. RAGE knockout mice have
enhanced survival in sepsis models, and RAGE blockade
attenuates the HMBG-1-induced inﬂammatory response
[20]. Other in vitro evidence suggests that toll-like recep-
tors (TLR) 2 and 4 may participate in HMGB1 signaling
[21, 22].
HMGB1 release from cells
Cells release HMGB1 following cell activation or cell
death, two processes central in inﬂammation. In activated
Fig. 1 This schematic depicts MP and HMBG1 release from cells
and subsequent immunologic effects. Microparticles (MPs) and
extracellular HMGB1 share several similar biological activities. Both
MPs and HMGB1 are released from several cell types following
activation, necrosis or apoptosis. MPs achieve release from cells via
budding and retain cell surface markers of parent cells. HMBG1
protein becomes biologically active after release from the nucleus and
extrusion into the extracellular space. Both MPs and HMBG1 exert
pro-inﬂammatory effects, including expression of inﬂammatory genes
and cytokines, upregulation of endothelial cell adhesion molecules,
and stimulation of dendritic cells
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cytoplasm, enters lysosomes and, via exocytosis, reaches
the extracellular milieu [23]. During the process of trans-
location, HMGB1 is phosphorylated [24]. As HMGB1
contains no signal sequence, the protein does not travel
through the Golgi apparatus or endoplasmic reticulum [25].
In contrast, during necrosis, HMGB1 readily leaves cells,
likely because its binding to DNA is weak in comparison
to that of the histones, for example. As a result, when cell
permeability breaks down during necrotic cell death,
HMGB1 diffuses away from chromatin to enter the extra-
cellular space. At present, Western blotting is the primary
approach for measuring extracellular HMGB1.
While initial studies suggested that apoptotic cells do
not release HMGB1 even when undergoing secondary
necrosis, recent observations indicate that apoptotic death
is also a setting for the release of this protein [25]. Fol-
lowing induction of apoptosis in Jurkat T cells by a variety
of chemical agents, HMGB1 appears in the medium as
shown by Western blotting; confocal microscopy can
also demonstrate the translocation of HMGB1 during this
death process [26]. Together, these ﬁndings suggest that,
depending upon the cell type and the stimulus for death,
HMGB1 release can follow apoptosis as well as necrosis
and therefore mark death irrespective of the biochemical
changes occurring in cells during these processes.
HMGB1 in inﬂammatory and autoimmune diseases
HMGB1 was initially described as an inﬂammatory protein
released in vitro by LPS-stimulated macrophages and as a
late mediator of murine LPS-induced sepsis [27]. Sub-
sequent studies in animal models provided support for
the role of HMGB1 in sepsis, including the attenuation of
murine sepsis by anti-HMBG1 antibodies [27]. Further
studies demonstrated that patients with sepsis have elevated
HMGB1 levels which increase with disease severity.
Beyond its role in sepsis, HMGB1 has been implicated in
the pathogenesis of a broad spectrum of acute and chronic
inﬂammatory conditions with elevated levels in the clinical
settings of acute lung injury, cancer, inﬂammatory bowel
disease, Sjogren’s syndrome, Churg–Strauss syndrome,
SLE and RA [28–31]. In fact, HMGB1 may be an autoan-
tigen recognized by perinuclear anti-neutrophil cytoplasmic
antibodies (p-ANCA) [32].
Rheumatoid arthritis
In both animal models of inﬂammatory arthritis and in
patients with RA, elevated levels of both intra- and extra-
cellular HMGB1 are seen in synovial tissue [33]. The
synovial ﬂuid of patients with RA also shows enhanced
levels of HMGB1 compared to that of osteoarthritis con-
trols [34]. Further supporting the role of HMGB1 in
inﬂammatory arthritis is the observation that intra-articular
injection of HMGB1 into rodent knee joints induces
synovitis and stimulates release of proinﬂammatory cyto-
kines from synovial macrophages [35]. In animal models
of collagen-induced arthritis, anti-HMGB1 antibody can
produce clinical improvement in the joint count, joint
pathology and cachexia similar to that seen with anti-TNFa
therapy [36]. Studies investigating serum levels of HMGB1
in RA have yielded mixed results [37, 38]. Sera of ANA
positive children with pauciarticular juvenile RA dem-
onstrate antibodies to HMGB1 or HMGB-2 [39, 40].
Together, these observations suggest that HMGB1 is a
mediator of inﬂammatory arthritis and may serve as a
potential therapeutic target.
Systemic lupus erythematosus
Because it can induce proinﬂammatory cytokines, HMGB1
has emerged as a potential pathogenic protein in SLE. In
fact, elevated levels of anti-HMGB1 antibody are present
in the serum of patients with SLE and increased extracel-
lular HMGB1 expression is seen in biopsies of cutaneous
lupus lesions [37, 41]. Of particular interest is the ﬁnding
that, in vitro, HMGB1 is present in DNA-containing
immune complexes that stimulate TLR9-RAGE mediated
dendritic cell production of cytokines, including interferon-
a. These complexes also bind to and activate B cells via
RAGE [42]. Additionally, anti-dsDNA sensitive, nephrit-
ogenic T cell lines from patients with active lupus nephritis
proliferate in response to HMG proteins [43]. As SLE is a
disease characterized by the formation of autoantibodies
to cell nucleus constituents, high levels of cytokine ex-
pression (particularly interferon-a), formation of immune
complexes, and autoreactive B cells, these data support the
role of HMGB1 in the pathogenesis of SLE. Studies
assessing the efﬁcacy of blocking HMGB1 activity in SLE
are needed to further elucidate the role of this novel
inﬂammatory protein in SLE.
Microparticles and their function
Like HMGB1, MPs are released from activated and dying
cells and promote inﬂammation. Originally described as
inert ‘‘platelet dust,’’ MPs are small (0.1–1 lm) membrane-
bound vesicles that circulate in the blood [44]. While
platelet-derived MPs are the most abundant particle species
in peripheral blood, circulating MPs can also arise from
lymphocytes, monocytes, endothelial cells, and other cell
types. MPs contain membrane, cytoplasmic and nuclear
components characteristic of their precursor cells [45].
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potently active physiologically, and can mediate inﬂamma-
tion, hemostasis, thrombosis, angiogenesis, and vascular
reactivity. Because of their small size, MPs widely circulate
throughout the vasculature, allowing participation in both
localandlong-rangesignaling.Intheirinteractionwithcells,
MPs bind via surface ligands, representing a kind of direct
long-distance cell–cell communication for cells typically
remote from each other. Furthermore, in a novel mechanism
for the intercellular interaction, MPs can transfer surface
molecules, including receptors, to other cells, as well as
exchange membrane and cytoplasmic proteins [46, 47].
Receptor transfer can enlarge the responses that can be
mounted by a given cell type; such transfer can also confer
sensitivity to infection by an organism (e.g., HIV), requiring
a particular cell surface molecule to allow entry [48].
Since platelet MPs were the ﬁrst species identiﬁed,
investigation of the role of these structures initially focused
on the clotting system. MPs play a role in normal hemo-
stasis and also have diverse properties that could promote
the pathogenesis of thrombotic disorders. Phosphatidyl-
serine and tissue factor are both exposed on the outer
membranes of MPs and are central players in the coagu-
lation cascade. MPs also interact with factors Va, VIII, and
IXa, thereby facilitating assembly of the prothrombinase
complex [49–52]. Among other activities, platelet MPs
bind b-2-glycoprotein-1 antibodies, suggesting a possible
role in antiphospholipid antibody syndrome (APS) [53]. As
shown in in vitro experiments, MPs isolated from patients
in various clinical settings (including sepsis, thrombotic
thrombocytopenic purpura, sickle cell disease and cardio-
pulmonary bypass grafting) have procoagulant activity
[54–57]. This activity may be relevant clinically since MP
concentrations are elevated in prothrombotic disorders
including acute coronary syndromes, venous thromboem-
bolism, heparin-induced thrombocytopenia, vasculitis,
paroxysmal nocturnal hemoglobinuria and thrombotic
thrombocytopenic purpura [58–63].
In addition to their thrombotic effects, MPs have potent
pro-inﬂammatory activities and are potentially important
mediators of autoimmune and inﬂammatory diseases.
Among these activities, platelet MPs can induce the binding
of monocytes to endothelial cells and promote survival of
hematopoietic cells [64]. Furthermore, platelet MPs can
promote leukocyte–leukocyte aggregation, likely due to
interactions between P-selectin expressed on platelet MPs
and itsligand onleukocytes [65].The mechanismsby which
MPs mediate these effects may include the transfer of ara-
chidonic acid to other cells, leading to increased adhesion of
monocytes toendothelium [47,66].Other pro-inﬂammatory
roles of MP include the secretion of IL-1b [67].
In contrast to actions promoting inﬂammation, T-cell-
derived MPs can induce macrophage apoptosis. This
killing action can potentially impair a key element of the
immune system and in turn trigger MP release from the
dying macrophage to augment other immunological and
vascular events [68].
Microparticle release from cells
Similar to HMGB1, activation and cell death promote MP
release, and the exact mechanisms underlying these pro-
cesses remain unknown. During cell activation by a variety
of stimuli, a rise in intracellular calcium is followed
by remodeling of the plasma membrane. This membrane
modiﬁcation can cause phosphatidylserine exposure and
bleb formation, leading to the extrusion of MPs to the
extracellular space [69]. During apoptosis, MP release
occurs in association with membrane blebbing, a charac-
teristic feature of programmed cell death. Blebbing
involves a dynamic redistribution of cellular contents,
perhaps related to volume stress that occurs as cells die.
Rho-associated kinase 1, ROCK-1, an effector of Rho
GTPases, is essential for apoptotic membrane blebbing
[68]. Not all cells bleb, however, and the blebbing process
can differ during the stage of apoptosis. Like HMGB1, MP
release appears to occur late in the cell death process and
may occur concurrently with cell fragmentation and the
formation of apoptotic bodies; apoptotic bodies represent
shrunken and collapsed cells with nuclear fragmentation.
Any eukaryotic cell undergoing activation or death
should theoretically release MPs, but most research has
focused on hematopoietic cell types (e.g., platelets, leu-
kocytes and erythrocytes) as well as vascular cells
including endothelial cells. Other cells, including tumors,
smooth muscle cell and synovial cells, can also release
MPs, although these MPs may be more readily detected in
the tissue or origin or at sites of inﬂammation (e.g., in the
synovium or synovial ﬂuid), rather than the blood.
GiventhegenerationofMPsduringexocytosisorblebbing
of membranes, their origin can be tracked by cell-speciﬁc
protein markers. Thus, the presence of CD4, CD3 or CD8 on
the MP surface indicates lymphoid origin while platelet MPs
are marked by the expression of glycoprotein IIb–IIIa,
P-selectin/CD42a.Similarly,endothelialMPsdisplaysurface
CD31 or CD 146 [70, 71]. MPs can express a different set of
surfacemarkersthantheprecursorcells,however,ashasbeen
observed with erythrocyte MPs [72]. The rules for the incor-
poration of different proteins into MPs are not known.
Microparticles in inﬂammatory and autoimmune
disease
Like HMGB1 and other consequences of cell activation or
death, elevated MP levels occur in the blood of patients
322 Mod Rheumatol (2008) 18:319–326
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characterized by disturbances of the immune system vas-
culature and include atherosclerosis, malignancy, multiple
sclerosis, vasculitis RA and SLE [62, 73–75].
Rheumatoid arthritis
In the pathogenesis of RA inﬂammation, angiogenesis and
thrombosis occur prominently, and the course of disease is
marked by accelerated atherosclerosis. MPs may play a
role in both articular and extraarticular manifestation,
suggesting that their levels could serve as biomarkers. In
patients with RA, platelet MPs levels in the blood are
elevated and appear to correlate with disease activity [76].
While platelet MPs are found in the plasma of RA subjects,
in the synovial ﬂuid, MPs derived from granulocytes and
monocytes dominate. Also present in synovial ﬂuid are T
cell, B cell, platelet and erythrocyte MPs. Synovial MPs
from patients with RA and other inﬂammatory arthritides
stimulate tissue factor/factor VII-dependent thrombin
generation. This local hypercoaguability may promote
intraarticular inﬂammation and the formation of ﬁbrin
clots, known as ‘‘rice bodies’’ [77].
In addition to promoting inﬂammation, MPs may con-
tribute to the erosion of cartilage and bone via effects
on synovial ﬁbroblast activity. As observed in in vitro
experiments using cells from patients with RA and other
inﬂammatory arthritides, incubation of ﬁbroblast-like
synoviocytes with autologous MPs induces expression of
MCP-1, IL-6, IL-8, VEGF, ICAM-1 and RANTES and a
decrease in GMCSF [78]. Furthermore, in in vitro studies,
MPs derived from T cells and monocytes can induce
synovial ﬁbroblast production of matrix metalloproteinases
(MMPs), including MMP-1, MMP-3, MMP-9 and MMP-
13 [78]. Taken together, these data suggest that MPs can
mediate cellular interactions responsible for synovial acti-
vation and articular destruction [77].
Systemic lupus erythematosus and APS
In view of the inﬂammation and vascular abnormalities
characteristic of SLE, the presence of MPs in peripheral
blood could provide a novel marker reﬂecting dysregulation
in the major cell populations underlying disease. Elevated
levels of platelet MPs have been described in individuals
with SLE [79]. In one study, patients with antiphospholipid
antibodies and elevated levels of platelet MPs but not
endothelial MPs predicted thrombosis [80]. In contrast,
another investigation found that endothelial MPs were
elevated in subjects with APS compared to controls with
and without non-APS thrombosis. Additionally, in vitro,
APS plasma induced a fourfold increase in the release of
endothelial MPs from human umbilical endothelial cells
[81]. In one study, MPs, primarily platelet-derived, were
elevated in SLE and correlated with thrombin generation,
although levels did not correlate with disease activity or the
presence of antiphospholipid antibody [82].
Conclusion
HMGB1 and MPs are novel mediators of inﬂammation,
liberated in the settings of cell activation and cell death.
Both are potentially important players in immune-mediated
diseases and can participate in local and long-range inter-
cellular communication. In many inﬂammatory and auto-
immune diseases, but particularly RA and SLE, MPs and
HMGB1 may play important roles in pathogenesis and, as
potential targets for treatment, may also provide new
opportunities for therapeutic intervention.
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